negatively regulated by FoxO3a (5, 6) , and this regulation may have a key function in the control of cellular metabolism during cancer initiation and progression. In their mini-review, Peck et al. describe the antagonism between FoxO3a and MYC, and its implication in cell metabolism and cancer development (7) . There is now ample evidence that the FoxA1 gene is mutated or amplified in some breast and prostate cancers. In their mini-review, Robinson and colleagues consider the accumulated evidence and provide insights into the implications of FoxA1 mutations in the context of breast and prostate cancers (8) . Beyond mutations, there are also indications that alternative splicing can produce oncogenic versions of Fox proteins. The FoxM1 gene is made up of 10 exons, of which exon Va and VIIa are alternatively spliced, giving rise to three distinct isoforms: FoxM1a, FoxM1b, and FoxM1c (3, 9) . In their perspective article, Lam et al. present experimental data to support their hypothesis that FoxM1b, which is overexpressed in cancer cells, has a greater oncogenic potential than FoxM1c (10) .
A thorough understanding of the regulation and role of these Fox proteins in cancer will allow us to exploit them as biomarkers for cancer diagnosis and targets for treatment (10) . Although earlier studies have shown that nuclear translocation of FoxO3a can lead to activation of genes important in cell cycle arrest and cell death, recent studies in cancer patient samples have revealed that sustained nuclear FoxO3a expression is associated with poor prognosis (11, 12) . In their commentary, Gong and Koo discuss the implications of nuclear FoxO3a expression and examine the molecular mechanism involved (13) . The principal roles played by FoxM1 in different aspects of cancer initiation and progression render it a prime target for pharmaceutical intervention (14) . In his perspective article, Teh summarizes the existing information on the role of FoxM1 in cancer initiation, progression, and drug resistance, and explores its usefulness as a biomarker for cancer screening, prognosis, and for monitoring drug treatment (15) . The thiazole antibiotics Siomycin A and Thiostrepton have been shown to be able to specifically target cancer cells, while leaving normal cells alone (16) . This effect depends on the ability of these antifungal agents to bind the forkhead DNA binding domain of FoxM1 directly (17) . In agreement, Gartel comments on the role of Siomycin A and Thiostrepton in blocking the transcriptional activity of FoxM1 and provide future perspectives (18) . Together, this collection of articles underscores the importance of Fox proteins during cancer initiation and development and proposes novel avenues for cancer diagnosis and treatment.
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